Abstract
Most cancer chemotherapeutic agents are administered at the maximum-tolerated dose (MTD) in short cycles with treatment breaks. However, MTD-based chemotherapies are often associated with significant toxicity and treatment breaks allow the opportunity for tumor regrowth and acquisition of chemoresistance. To minimize these drawbacks, a metronomic strategy, in which chemotherapeutics are administered at doses significantly below the MTD without treatment breaks, has been suggested by many investigators. The antitumor effect of metronomic chemotherapy may be partially due to inhibition of tumor angiogenesis, and it could be enhanced by a combination therapy, including antiangiogenic agents. In this study, we evaluated the synergistic effect of E10A, an adenovirus carrying the endostatin gene, the most potent inhibitors of tumor angiogenesis, in combination with weekly low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. The E10A induced mRNA and protein expressions of endostatin in H891 cells in vitro. E10A significantly enhanced the in vivo tumor growth inhibitory effect of cisplatin. Immunohistochemical analysis with a TUNEL (terminal deoxynucleotidyl transferase-mediated nick-end labeling) assay and anti-CD31 antibodies revealed that the combination of E10A and cisplatin induced high levels of cell apoptosis and inhibited tumor angiogenesis. Importantly, E10A increased the platinum concentrations in tumors to fivefold higher than that induced by cisplatin alone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–130.
Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004; 31: 778–785.
Kerbel RS, Kamen BA . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423–436.
Kamen BA, Rubin E, Aisner J, Glatstein E . High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18: 2935–2937.
Piccart-Gebhart MJ . Mathematics and oncology: a match for life? J Clin Oncol 2003; 21: 1425–1428.
Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–1047.
Folkman J . Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29 (Suppl 16): 15–18.
Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K . The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 2009; 20: 663–671.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.
Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL . Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000; 97: 4802–4807.
Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19: 29–34.
Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95: 3403–3411.
Cao Y, Liu Q . Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007; 97: 203–224.
Torimura T, Ueno T, Kin M, Taniguchi E, Nakamura T, Inoue K et al. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology 2006; 130: 1301–1310.
Rabik CA, Dolan ME . Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9–23.
Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522–1534.
Galanski M . Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 2006; 1: 285–295.
Pasquier E, Kavallaris M, Andre N . Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455–465.
Zhou LX . [Biological behavior of hypopharyngeal carcinoma]. Nippon Jibiinkoka Gakkai Kaiho 1997; 100: 59–67.
Li L, Huang JL, Liu QC, Wu PH, Liu RY, Zeng YX et al. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J Gastroenterol 2004; 10: 1867–1871.
Huang W, Flint SJ . Unusual properties of adenovirus E2E transcription by RNA polymerase III. J Virol 2003; 77: 4015–4024.
Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K . A replication-selective adenoviral vector for head and neck cancers. Arch Otolaryngol Head Neck Surg 2005; 131: 630–634.
Guo JY, Huo HR, Zhao BS, Liu HB, Li LF, Ma YY et al. Cinnamaldehyde reduces IL-1beta-induced cyclooxygenase-2 activity in rat cerebral microvascular endothelial cells. Eur J Pharmacol 2006; 537: 174–180.
Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P . Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994; 35: 1–9.
Bai RZ, Wu Y, Liu Q, Xie K, Wei YQ, Wang YS et al. Suppression of lung cancer in murine model: treated by combination of recombinant human endostatin adenovirus with low-dose cisplatin. J Exp Clin Cancer Res 2009; 28: 31.
Gately S, Kerbel R . Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7: 427–436.
Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64: 3994–4000.
Kaur H, Budd GT . Metronomic therapy for breast cancer. Curr Oncol Rep 2004; 6: 49–52.
Lin X, Huang H, Li S, Li H, Li Y, Cao Y et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007; 6: 648–653.
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–1886.
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–R24.
Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 2006; 66: 3360–3364.
Cairns R, Papandreou I, Denko N . Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006; 4: 61–70.
Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942–3950.
Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M . Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther 2004; 11: 1283–1289.
Acknowledgements
This research was supported by Japanese Research Project, Grant-in-aid for Scientific Research (B); project number 21390462 (TS), in part by Grants-in-Aid for Scientific Research; project number 20251283 and 21390462 (K-iN) and the Society for Promotion of International Oto-Rhino-Laryngology (SPIO), Japan (ZA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Adhim, Z., Lin, X., Huang, W. et al. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther 19, 144–152 (2012). https://doi.org/10.1038/cgt.2011.79
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2011.79
Keywords
This article is cited by
-
Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA combined with cisplatin inhibits cellular growth and induces apoptosis in HPV-positive head and neck cancer cells
Cancer Gene Therapy (2018)
-
Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma
Molecular Therapy (2014)
-
Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells
Journal of Translational Medicine (2013)
-
Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients
Cancer Chemotherapy and Pharmacology (2012)